Pfizer earnings per share 2024| Statista

Pfizer generated a net income of over eight billion U.S. dollars in 2024. The company reported basic net earnings per common share of 1.42 U.S. dollars.

The impact of rising costs on earnings per share

The net income of Pfizer dramatically increased around fourfold between 2023 and 2024, evident in the company’s net earnings per share, which increased by over one U.S. dollar. Rising research and development costs can be a contributing factor in the decrease in the net income. In relation to revenues, the pharmaceutical industry is one of the biggest investors in research and development.

Revenues increased due to COVID-19 vaccine

Thanks to record-breaking sales of COVID-19 vaccine Comirnaty, Pfizer generated its highest total revenues in the years 2021 and 2022. In general, the majority of Pfizer’s revenues comes from the manufacture and sale of its products, and revenues from the company’s domestic market of the United States accounts for a share of around 60 percent. Pfizer sells its pharmaceutical products in more than 125 countries worldwide, with the United States, China, and Japan being its three largest markets.

Earnings per share of Pfizer from 2008 to 2024 (in U.S. dollars)

Characteristic	Net earnings per common share
2024	1.42
2023	0.38
2022	5.59
2021	3.92
2020	1.65
2019	2.88
2018	1.9
2017	3.57
2016	1.18
2015	1.13
2014	1.44
2013	3.23
2012	1.96

01234567

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

February 2025

More information

Region

Worldwide, United States

Survey time period

2008 to 2024

Supplementary notes

Basic earnings per common share: net income attributable to Pfizer Inc. common shareholders.
This statistic was assembled from several editions of Pfizer's annual financial report.

Citation formats